Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Highlights from Lilly's Alzheimer's Disease Pipeline at the Alzheimer's Association International Conference® 2018 (AAIC® 2018)

      Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company) (PRNewsfoto/Eli Lilly and Company)

      News provided by

      Eli Lilly and Company

      Jul 20, 2018, 09:30 ET

      Share this article

      Share this article


      INDIANAPOLIS, July 20, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that new results from a number of studies across the company's Alzheimer's disease pipeline will be presented at the Alzheimer's Association International Conference (AAIC) in Chicago, July 22-26, 2018. Nearly 30 oral and poster presentations will underscore Lilly's focus on making a meaningful difference in the lives of people living with Alzheimer's through clinical development and collaboration.

      "Lilly's commitment to Alzheimer's research continues," said Phyllis Ferrell, vice president, Global Alzheimer's Disease Platform Team. "The research findings we are sharing at this year's meeting highlight our ongoing efforts to find solutions that may lead to a disease-modifying therapy. The patients and their loved ones we aim to help can't quit, and neither will we."

      Studies being presented about Lilly molecules include (please note, all times listed below are Central Daylight Time):

      Alzheimer's Disease Care Environment

      • Patterns of change in dependence levels for community dwelling Alzheimer's patients: 36-month results from the GERAS observational study
        Poster presentation, Sunday, July 22, 9:30AM-4:15PM
      • Do the minimal clinically important difference estimates for clinical outcome assessments for Alzheimer's disease differ by disease severity?
        Poster presentation, Monday, July 23, 9:30AM-4:15PM
      • Models of Patient Engagement in Alzheimer´s Disease (MOPEAD): a European multinational project to develop and test innovative patient engagement strategies
        Poster presentation, Tuesday, July 24, 9:30AM-4:15PM
      • Baseline findings from GERAS-US: a longitudinal cohort study of resource use and costs of mild cognitive impairment and mild dementia due to Alzheimer's Disease (AD) in the United States
        Oral presentation, Thursday, July 26, 11:45AM-12:00PM

      N3pG mAb and BACE Inhibitor Combination

      • Trailblazer-ALZ, a Phase 2 Disease-Modification Combination Therapy Trial Targeting Multiple Mechanisms of Action Along the Amyloid Pathway
        Poster presentation, Wednesday, July 25, 9:30AM- 4:15PM

      N3pG mAb

      • Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Intravenous Doses of LY3002813, a β-amyloid Plaque-specific Antibody, in Patients with Mild Cognitive Impairment due to Alzheimer's Disease or Mild to Moderate Alzheimer's Dementia
        Oral presentation, Sunday, July 22, 2:00-2:15PM

      Lanabecestat

      • Lanabecestat Does Not Affect Pharmacokinetics of the BCRP Substrate Rosuvastatin
        Poster presentation, Sunday, July 22, 9:30AM-4:15PM
      • Lanabecestat: Screening Performance from the AMARANTH Study
        Poster presentation, Wednesday, July 25, 9:30AM-4:15PM
      • Baseline Characteristics of Participants Randomized in the Phase 2/3 AMARANTH Study
        Oral presentation, Wednesday, July 25, 2:45-3:00PM

      Tau mAb

      • The Use of the Digital Clock Drawing Test (DCTclock™) in the Screening Phase of Clinical Trials for Alzheimer's Disease
        Poster presentation, Sunday, July 22, 9:30AM-4:15PM

      Solanezumab

      • The relationship between Tau PET and other AD biomarkers in autosomal dominant Alzheimer disease
        Poster presentation, Saturday, July 21, 12:30-1:45PM
        Oral presentation, Tuesday, July 24, 4:45-5:00PM
      • The relationship between Tau PET and age across the lifespan
        Oral presentation, Saturday, July 21, 8:45-9:00AM
        Poster presentation, Monday, July 23, 9:30AM-4:15PM
      • Impact of Disclosing Amyloid Imaging Results to Cognitively Normal Research: The A4 Experience
        Oral presentation, Sunday, July 22, 8:00-8:15AM
      • The Anti-Amyloid Treatment in Asymptomatic AD (A4) Study- Report of Screening Data Results
        Oral presentation, Sunday, July 22, 8:15-8:30AM
      • DIAN-TU Adaptive Prevention Trial Launch and Baseline Data
        Oral presentation, Sunday, July 22, 8:30-8:45AM
      • Predicting Amyloid Burden in Screening for Preclinical AD Prevention Trials
        Oral presentation, Sunday, July 22, 9:00-9:15AM
      • Tau PET in A4: Preliminary Report
        Poster presentation, Wednesday, July 25, 9:30AM-4:15PM
      • Computerized Cognitive Composite (C3) Performance Differences between Aβ+ and Aβ- normal older adults screened for the A4 (Anti-Amyloid in Asymptomatic AD) Study
        Poster presentation, Wednesday, July 25, 9:30AM-4:15PM
      • Brain Amyloid Burden, Sleep, and circadian Rest/Activity Rhythms: Baseline Findings from A4 and LEARN
        Poster presentation, Wednesday, July 25, 9:30AM-4:15PM

      Selective BACE 1 Inhibitor

      • The role of BACE1 Inhibition on Aβ Pathology in Aged PDAPP Mice
        Poster presentation, Monday, July 23, 9:30AM-4:15PM

      Biomarkers in Alzheimer's Disease

      • Standardization, Quality Control & Regulated Issues for Fluid Biomarkers (Topic 5: Workshop – The Basics of Fluid Biomarkers in Alzheimer's Disease)
        Workshop presentation, Friday, July 20, 11:30AM-12:15PM
      • Comparison between Three Volumetric MRI Z-Score Norming Methods across the Alzheimer Disease Spectrum
        Poster presentation, Saturday, July 21, 12:30-1:45PM; Sunday, July 22, 9:30AM-4:15PM
      • Age-Normed Diffusion Basis Spectrum Imaging (DBSI) Cell Ratios to Assess Neuroinflammation in Alzheimer's Disease Clinical Trials
        Poster presentation, Saturday, July 21, 12:30-1:45PM; Tuesday, July 24, 9:30AM-4:15PM
      • A Simple Method for Defining Atrophy Subtypes in Individual Subjects across the Alzheimer Disease Spectrum
        Poster presentation, Saturday, July 21, 12:30-1:45PM; Wednesday, July 25, 9:30AM-4:15PM
      • Subtypes of Neurodegeneration in Alzheimer Disease: A Head-to-Head Comparison of Four Brain Atrophy Subtype Algorithms in ADNI
        Poster presentation, Sunday, July 22, 9:30AM-4:15PM
      • Measurement of endogenous mouse tau in cerebrospinal fluid from aged PDAPP mice following treatment with Aβ lowering compounds
        Poster presentation, Sunday, July 22, 9:30AM-4:15PM
      • Mapping Genomic Consequences of Alzheimer's Disease Pathology in Amyloid and Tau Mouse
        Poster presentation, Tuesday, July 24, 9:30AM-4:15PM

      Flortaucipir PET Tracer

      • Lobar classification of tau PET images in the EXPEDITION3 trial
        Poster presentation, Saturday, July 21, 12:30-1:45PM
        Oral presentation, Tuesday, July 24, 4:30-4:45PM
      • Alzheimer Disease Tau PET Subtypes in the ADNI Sample
        Poster presentation, Wednesday, July 25, 9:30AM-4:15AM

      About Alzheimer's Disease

      Alzheimer's disease is a fatal illness that causes progressive decline in memory and other aspects of cognition.1 Dementia due to Alzheimer's disease is the most common form of dementia, accounting for 60 to 80 percent of all cases.2 There are currently an estimated 50 million people living with dementia around the world, with numbers expected to increase to nearly 75 million by 2030 and 132 million by 2050.  Almost 10 million new cases of dementia are diagnosed each year worldwide, implying one new case approximately every 3 seconds. The current total annual societal and economic estimated cost of dementia is $818 billion USD worldwide and this year may rise above a trillion USD.3

      About Eli Lilly and Company
      Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/newsroom/social-channels. P-LLY    

      This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about investigational treatments and diagnostics for Alzheimer's disease and reflects Lilly's current belief. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with the results to date or that these investigational compounds or diagnostics will achieve primary study endpoints or receive regulatory approvals.  For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

      1 Alzheimer's Association. What is Alzheimer's? http://www.alz.org/alzheimers_disease_what_is_alzheimers.asp. Accessed April 2018. 
      2 Alzheimer's Association. What is Dementia? http://www.alz.org/what-is-dementia.asp. Accessed April 2018. 
      3 Alzheimer's Disease International. Dementia Statistics. https://www.alz.co.uk/research/statistics. Accessed April 2018.

      Refer to: 

      Nicole Hebert; [email protected]; 317-701-9984 (media)


      Kevin Hern; [email protected]; 317-277-1838 (investors)    

      SOURCE Eli Lilly and Company

      Modal title

      Also from this source

      Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale

      Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale

      Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), will present new data across its cardiometabolic...

      Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020

      Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020

      Eli Lilly and Company (NYSE: LLY) today broke ground on a $3.5 billion manufacturing facility in Pennsylvania's Lehigh Valley. The site is one of 10...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Clinical Trials & Medical Discoveries

      Clinical Trials & Medical Discoveries

      Trade Show News

      Trade Show News

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.